Skip to main content
logo
CASI Pharmaceuticals, Inc. (CASIF)
OTCMKTS · Delayed Price · Currency is USD
0.1288
+0.0088 (7.33%)
At close: Aug 11, 2026

CASI Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
20.7120.7128.5433.8843.1130.17
Revenue Growth
-27.42%-27.42%-15.77%-21.41%42.89%99.25%
Gross Profit
10.0810.0811.1520.0527.2817.61
Operating Income
-45.01-45.01-39.62-25.08-34.03-41.84
Net Income
-48.06-48.06-39.26-26.96-41.01-36.65
Earnings Per Share
-2.59-2.59-2.56-2.02-3.01-2.70
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
5.635.6316.0930.7751.3448.57
Total Debt
24.4324.4318.3918.900
Net Cash (Debt)
-18.8-18.8-2.2911.8751.3448.57
Net Cash Growth
----76.87%5.69%-25.37%
Net Cash Per Share
-1.01-1.01-0.150.893.763.57

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-20.75-20.75-29.22-19.97-21.09-26.84
Capital Expenditures
-0.02-0.02-0.22-0.2-5.61-8.95
Free Cash Flow
-20.77-20.77-29.45-20.17-26.7-35.79
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
48.65%48.65%39.06%59.19%63.28%58.38%
Operating Margin
-217.30%-217.30%-138.84%-74.03%-78.95%-138.68%
Pretax Margin
-221.47%-221.47%-133.40%-77.61%-86.83%-118.81%
Profit Margin
-232.03%-232.03%-137.57%-77.51%-93.39%-118.81%
FCF Margin
-100.28%-100.28%-103.19%-59.54%-61.94%-118.63%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-37.2937.29---
PS Ratio
0.130.841.542.830.563.71